Date: 2011-01-05
Type of information: R&D agreement
Compound: companion test to measure the level of activated Natural Killer (“aNK”) cells in order to select patients to be treated with TG4010 (MVA-MUC1-IL2 immunotherapy candidate, is about to enter into a pivotalPhase IIb/III clinical trial for the treatment of Non-Small Cell Lung Cancer)
Company: Transgene (France) Beckman Coulter (USA)
Therapeutic area: Cancer Oncology
Type agreement: R&D
Development
Action mechanism:
Disease: non small cell lung cancer
Details: Transgene has signed an agreement with Beckman Coulter, Inc, under which Beckman Coulter will develop for Transgene a companion test that measures the level of activated Natural Killer (“aNK”) cells in order to select patients to be treated with TG4010. The companion test will measure triple positive (CD16+, CD56+, CD69+ / CD45+ lymphocytes) activated NK cells (the “aNK Test”). It will come in addition to a test developed by Ventana Medical System, Inc. that allows Transgene to identify patients with MUC1 positive tumor cells (the “MUC1 Test”). The MUC1 and aNK tests will be used in the upcoming Phase IIb/III clinical trial with TG4010 in NSCLC. If the trial is successful and regulatory approvals are granted for TG4010 and for the tests, these companion tests could then serve as a tool for physicians to identify patients who can be treated with TG4010 upon commercialization. The Phase IIb/III trial with TG4010 in NSCLC is expected to start recruitment in mid-2011.
Financial terms:
Latest news:
